NMPA is the regulatory body that manages the launch of pharmaceutical products in China. It authorizes your product after drug classification, clinical development, quality, and CMC documentation, technical review, inspections, testing, marketing authorization, and extensive post-market responsibilities.
The current regulatory system here also emphasizes drug innovation, the Marketing Authorization Holder (MAH) system, lifecycle quality management, and accelerated pathways. It looks for acceptance of appropriate overseas clinical evidence and pharmacovigilance.
This guide explains how NMPA drug registration works in 2026. Know the documents companies need, which accelerated pathways are available, and what happens after approval.
Regulatory Body of the Pharmaceutical Industry in China
China’s national drug regulator is the National Medical Products Administration (NMPA). The country’s core pharmaceutical legislation is the Drug Administration Law of the People’s Republic of China. It covers drug development, manufacturing, distribution, use, and regulatory oversight.
The regulatory framework is supported by the Provisions for Drug Registration and numerous NMPA/CDE technical guidelines and standards.
Drugs Classification for Registration
According to the current provisions, the following categories are prevalent during drug registration:
Chemical Drugs
Chemical pharmaceuticals are further divided into applicable registration categories. It depends on factors like the innovative nature of the product, whether it is modified, generic, or already marketed domestically or overseas.
Biological Products
Biological products have their own registration classifications and technical requirements. These cover products intended for therapeutic and preventive use.
Traditional Chinese Medicines
TCMs follow a separate registration framework reflecting their particular characteristics, evidence base, and development approach.
You should know the correct classification before the registration strategy. It’ll help with the required studies, supporting documentation, clinical pathway, and review strategy.
What is NMPA Drug Registration?
Article 24 of China’s Drug Administration Law states that drugs to be marketed in China must obtain a drug approval license from the national drug regulatory authority. It is subject to specified exceptions for some Chinese medicinal materials and prepared slices of Chinese crude drugs. Applicants must provide authentic, sufficient, and reliable information about the drug’s safety, efficacy, and quality management.
This explanation makes registration more than a final dossier submission. It can encompass the entire development journey as follows:
Preclinical Development → Clinical Trial Application → Clinical Development → Marketing Authorization Application → Technical Review → Inspection/Testing → Approval → Post-Market Compliance
Can Foreign Pharma Companies Register Drugs in China?
Yes. China’s current framework allows overseas-manufactured pharmaceuticals to obtain marketing authorization. However, overseas approval should not be interpreted as automatic Chinese approval. A company should assess how its existing global development package fits NMPA requirements mentioned below:
- Product registration category
- CMC and quality documentation
- Existing clinical evidence
- Applicability of overseas clinical trial data
- Racial/ethnic sensitivity
- Chinese patient needs
- Manufacturing arrangements
- Inspection requirements
- Post-market obligations
Drugs already approved in the United States, EU, Japan, or other international markets must follow this.
Step-by-Step NMPA Drug Registration Process
The process is easier to understand when treated as a regulatory pathway rather than a collection of individual submissions. Here it is written below:
Step 1: Decide the Registration Category
Start by establishing whether the product is a chemical drug, biological product, or TCM and determine the applicable registration classification. This decision influences the evidence expected throughout the application.
Step 2: China Regulatory Gap Assessment
Compare the existing FDA, EMA, or other global dossier against current Chinese requirements for internationally developed products. Pay close attention to CMC, clinical evidence, racial sensitivity, manufacturing, specifications, and China-specific administrative information.
Step 3: Prepare the Clinical Trial Application
Where Chinese clinical development is required, compile the CMC, pharmacology, toxicology, and other evidence needed to support the proposed studies.
Step 4: Conduct Applicable Clinical Studies
Complete the required clinical development according to applicable Chinese GCP and NMPA/CDE requirements. Evaluate whether overseas data can fully or partly support the Chinese application for globally developed drugs.
Step 5: Prepare the Marketing Authorization Dossier
First, the studies supporting registration should be completed. The product specifications should be established, and commercial-scale manufacturing process validation and registration inspection/testing preparations completed. Then, the applicant may file the marketing authorization application.
Step 6: Submit the Marketing Authorization Application
The complete application is submitted for regulatory acceptance and review.
Step 7: CDE Technical Review
The Center for Drug Evaluation assesses the evidence supporting the product’s quality, safety, and efficacy.
Step 8: Inspection and Testing
Manufacturing-site inspection, registration testing, or specification verification may be required depending on the product and application.
Step 9: NMPA Decision
Marketing authorization may be granted after successful completion of the applicable review and regulatory requirements.
Step 10: Maintain Lifecycle Compliance
The MAH assumes continuing obligations involving product quality, manufacturing, pharmacovigilance, changes, and other post-market activities after approval.
NMPA Drug Registration Documentation Requirements
The exact dossier depends on the product and registration category. Pharmaceutical companies should therefore avoid treating a generic checklist as sufficient for every submission. A comprehensive dossier will generally need to address several major areas like the following:
Administrative Information
China-specific administrative and application documentation identifies the applicant, product, manufacturers, and regulatory basis for the submission.
Quality and CMC Documentation
The quality package can include detailed information concerning:
- Drug substance
- Drug product
- Formulation
- Manufacturing processes
- Process controls
- Specifications
- Analytical procedures
- Method validation
- Reference standards
- Container-closure systems
- Stability
Nonclinical Evidence
Depending on the product and development pathway, pharmacology, pharmacokinetics, and toxicology studies may be required to support clinical development and/or marketing authorization.
Clinical Evidence
The dossier should contain the clinical evidence needed to demonstrate safety and efficacy for the proposed indication, including appropriate clinical study reports and analyses. For overseas products, supporting global clinical data should be accompanied by an appropriate assessment of its relevance to Chinese patients.
Labeling and Product Information
Proposed labeling and package information should also be prepared in accordance with applicable Chinese regulatory requirements. The dossier should ultimately tell one consistent regulatory story across development, manufacturing, quality, clinical evidence, and proposed use.
Does China Accept Overseas Clinical Trial Data?
Yes. However, acceptance is based on scientific evaluation rather than a blanket rule that foreign data automatically replace Chinese clinical studies.
NMPA guidance for drugs marketed overseas but not yet marketed in China provides for the evaluation of overseas clinical data. Regulators consider factors including the following:
- Quality and completeness of clinical evidence
- Safety and efficacy, racial sensitivity
- Pharmacokinetic/pharmacodynamic characteristics
- Overall benefit-risk profile for Chinese patients
The data should be authentic, accurate, complete, and traceable, with clinical trials conducted according to internationally accepted GCP principles.
Timeline of NMPA Drug Registration
Under the current Drug Registration Provisions, the standard review timeline for a drug marketing authorization application is 200 days. Other important statutory timelines are included in the table below:
| Regulatory Activity |
Published Timeline
|
| Clinical Trial Application review | 60 days |
| Standard Marketing Authorization Application review | 200 days |
| Priority Review | 130 days |
| Priority review for qualifying urgently needed rare-disease drugs marketed overseas | 70 days |
| Sample testing | 60 days |
| Sample testing + specification verification | 90 days |
These figures should not be advertised as guaranteed end-to-end registration timelines. The actual market-entry project can take longer because of clinical development, dossier preparation, inspections, testing, supplementary information, regulatory questions, and other product-specific factors.
Marketing Authorization Holder (MAH) in China
Under Article 6 of the Drug Administration Law, a Market Authorization Holder is legally responsible for the drug’s safety, efficacy, and quality management throughout research and development, manufacturing, distribution, and use.
Once an applicant obtains the relevant drug approval, it assumes MAH responsibilities. This lifecycle responsibility means approval cannot be treated as the point where regulatory accountability ends. MAHs have obligations spanning areas like the following:
Quality management → Manufacturing oversight → Distribution → Pharmacovigilance → Post-marketing research → Risk management
NMPA clarified at implementation that entities holding relevant drug registration certificates are treated as MAHs and bear responsibilities throughout the product lifecycle.
Accelerated Drug Registration Pathways in China
China has established mechanisms intended to accelerate the development and/or review of eligible drugs. These are given below:
Breakthrough Therapy Drug Procedure
An innovative or modified new drug may qualify for breakthrough therapy designation during clinical development. It happens when it addresses a serious life-threatening disease or a disease that seriously affects quality of life. Or, one of the following two happens:
- No effective preventive or treatment method is available
- Sufficient evidence indicates a significant clinical advantage over existing treatments
The CDE provides additional regulatory support to eligible products during development.
Conditional Approval
China’s Drug Administration Law permits conditional approval in some circumstances. It’s applicable for drugs addressing severe life-threatening diseases without effective treatment and drugs urgently needed for public health. Available clinical evidence demonstrates efficacy and predictable clinical results. Post-approval obligations may apply.
Priority Review and Approval
Eligible products can receive priority review. Under the current Drug Registration Provisions, the marketing-authorization review timeline for priority applications is 130 days. For qualifying rare-disease drugs with urgent clinical needs that have already been marketed overseas, the priority review timeline can be 70 days.
Special Review and Approval
Special review is intended for exceptional circumstances such as public-health emergencies. NMPA can accelerate acceptance, review, inspection, and testing for relevant therapeutic or preventive products. It should therefore not be confused with an ordinary commercial fast-track route.
What Happens After NMPA Drug Approval?
The law specifically asks a pharmacovigilance system to monitor, identify, assess, and control adverse reactions and other harmful drug-related effects. MAHs must maintain appropriate systems for life cycle quality and safety management. In fact, the post-approval responsibilities can include the following:
- Pharmacovigilance and adverse-reaction monitoring
- Product quality management
- Post-marketing research where required
- Manufacturing oversight
- Traceability
- Risk management
- Post-approval change control
- Continued regulatory compliance
2026 Update: China Strengthens Oversight of Contract Drug Manufacturing
NMPA published its English version of Announcement No. 134 of 2025 in April 2026. It reinforces responsibilities for both MAHs and contract manufacturers.
Contract manufacturers have to maintain an effective quality management system. They should comply with drug GMP and manufacture according to approved standards, formulations, and processes. They must also evaluate prospective MAHs and products before accepting contract manufacturing and maintain appropriate risk-management and change-control systems. The requirements emphasize coordination between the MAHs’ and contract manufacturers’ quality systems.
For example, the announcement requires contract manufacturers to cooperate with MAHs in activities including risk assessment, validation, communication, review, and risk control. It also establishes additional expectations for higher-risk products such as sterile drugs.
For companies relying on CDMOs, supplier qualification and quality agreements should therefore be treated as core regulatory activities—not procurement formalities.
Conclusion
China’s pharmaceutical regulatory system has become increasingly aligned with life cycle regulation, innovation, and risk-based oversight. But that doesn’t make market entry a copy-and-paste exercise.
The most important work for overseas manufacturers happens before the submission of the NMPA application. You can prevent avoidable delays later by understanding how existing clinical data can be leveraged and following the process mentioned in the blog.
Artixio supports pharmaceutical companies with regulatory compliance and market entry in China. If you’re planning to register a pharmaceutical product, contact Artixio at info@artixio.com.
FAQs
Does a pharmaceutical product need NMPA approval before being sold in China?
Generally, yes. Article 24 of China’s Drug Administration Law requires drugs marketed in China to obtain a drug approval license, subject to specified exceptions concerning certain Chinese medicinal materials and prepared slices of Chinese crude drugs.
Can a foreign pharmaceutical company register a drug in China?
Yes. Overseas-manufactured products can obtain authorization for the Chinese market. The regulatory strategy should account for the product’s registration category, existing global evidence, China-specific requirements, and applicable clinical, quality, and manufacturing requirements.
What is the 60-day clinical trial rule in China?
For a drug clinical trial application, the authority has 60 working days from acceptance to decide whether to approve it. Under the Drug Administration Law, if the sponsor is not notified within that period, the application is considered approved.
